hSTC810 for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called hSTC810, an experimental antibody therapy, to determine its safety and tolerability for people with advanced solid tumors, such as those in the liver or lungs. Researchers examine how the body processes the drug and whether it shows any signs of effectiveness against cancer. Participants receive varying doses to identify the optimal and safest amount. This trial may suit individuals with advanced cancer who have not recently undergone other treatments and do not have active infections or major health issues. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new therapy.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications, but you cannot have received anti-cancer treatment, radiotherapy, or major surgery within 4 weeks before starting the study. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that hSTC810 is likely to be safe for humans?
Research has shown that hSTC810, also known as Nelmastobart, was tested for safety in earlier studies. These studies involved patients with advanced solid tumors and found that hSTC810 was generally safe. Participants handled the treatment well, and no major safety issues were reported. Early results also suggested that the treatment might be effective. For those considering joining this trial, this early research offers a reassuring view of the treatment's safety.12345
Why do researchers think this study treatment might be promising?
Unlike the standard treatments for solid tumors, which often include chemotherapy, radiation, or surgery, hSTC810 is unique because it introduces a novel mechanism of action. Researchers are excited about hSTC810 because it targets specific pathways within cancer cells, potentially leading to more precise and effective results with fewer side effects. This targeted approach could offer new hope for patients whose tumors don't respond well to existing therapies, providing a more tailored and potentially more successful treatment option.
What evidence suggests that hSTC810 might be an effective treatment for solid tumors?
Research shows that hSTC810, also known as Nelmastobart, is a specially designed antibody targeting a protein found in many solid tumors. Studies have found that this treatment can help patients with advanced solid tumors by slowing tumor growth. It blocks a protein that aids cancer cell survival. Some patients have responded well, with their cancer not worsening. While early results are promising, further research is needed to confirm its effectiveness.12567
Who Is on the Research Team?
Medical director
Principal Investigator
STCube, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors who have a life expectancy of at least 12 weeks, can consent to the study, and agree to use contraception. They must have at least one measurable tumor and be in good physical condition (ECOG PS ≤1). People with active brain metastases, recent cancer treatments or major surgeries, certain infections like hepatitis or COVID-19, autoimmune diseases needing treatment within 2 years, severe allergies to checkpoint inhibitors, or serious heart conditions cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose-escalation
Participants receive escalating doses of hSTC810 to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for overall survival and other long-term outcomes
What Are the Treatments Tested in This Trial?
Interventions
- hSTC810
Find a Clinic Near You
Who Is Running the Clinical Trial?
STCube, Inc.
Lead Sponsor